-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60

Benzinga·11/03/2026 14:57:05
RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $62 to $60.